157 related articles for article (PubMed ID: 15176055)
1. Molecular alterations associated with LNCaP cell progression to androgen independence.
Shi XB; Ma AH; Tepper CG; Xia L; Gregg JP; Gandour-Edwards R; Mack PC; Kung HJ; deVere White RW
Prostate; 2004 Aug; 60(3):257-71. PubMed ID: 15176055
[TBL] [Abstract][Full Text] [Related]
2. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
4. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
5. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models.
Kojima S; Mulholland DJ; Ettinger S; Fazli L; Nelson CC; Gleave ME
Prostate; 2006 Jun; 66(9):971-86. PubMed ID: 16541420
[TBL] [Abstract][Full Text] [Related]
8. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
[TBL] [Abstract][Full Text] [Related]
9. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
10. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells.
Lu S; Ren C; Liu Y; Epner DE
Int J Oncol; 2006 Jan; 28(1):245-51. PubMed ID: 16328002
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
12. Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression.
Grant ES; Batchelor KW; Habib FK
Prostate; 1996 Dec; 29(6):339-49. PubMed ID: 8977630
[TBL] [Abstract][Full Text] [Related]
13. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
14. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
15. Differential phosphoprotein levels and pathway analysis identify the transition mechanism of LNCaP cells into androgen-independent cells.
Wang HQ; Yang B; Xu CL; Wang LH; Zhang YX; Xu B; Ji JT; Sun YH
Prostate; 2010 Apr; 70(5):508-17. PubMed ID: 19937597
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
Oka H; Chatani Y; Kohno M; Kawakita M; Ogawa O
Int J Urol; 2005 Oct; 12(10):899-905. PubMed ID: 16323984
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of proliferation and expression of AR/PSA by herbal supplement Equiguard in LNCaP cells cultured in androgen-proficient FBS and androgen-deficient charcoal-stripped FBS is correlated with increased serine-15 phosphorylation of the tumor suppressor gene p53.
Lu X; Guo J; Hsieh TC; Wu JM
Anticancer Res; 2003; 23(3B):2489-98. PubMed ID: 12894532
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
[TBL] [Abstract][Full Text] [Related]
20. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
